

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Maurizio Zanetti

Serial No.:

09/788,110

02/15/2001

Group No.: 1642

Examiner: Ungar, S.

Entitled:

Filed:

Composition and Method For Inducing and Enhancing A Telomerase

Reverse Transcriptase-Reactive Cytotoxic T Lymphocyte Response

INTERVIEW SUMMARY

MS Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 3, 2007

Cliff Cannon-Cin

Dear Madam:

On March 1, 2007, Susan Ungar and Christine Lekutis discussed the 112 rejections of record. Applicant understood that amending the claim set to recite one or more of "SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:21 and SEQ ID NO:22" would likely overcome the written description rejections. In addition, Applicant understood that the Office would consider additional claim amendments in view of the enablement and indefiniteness rejections.

Dated: _____April 3, 2007

Christine A. Lekutis Registration No. 51,934

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 415.904.6500